La cadena de opciones muestra datos clave de las opciones de acciones de Atossa Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Atossa Therapeutics..

Atossa Therapeutics (NASDAQ:ATOS) Bolsa, Cadena de Opciones

ATOSSA THERAPEUTICS INC

Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Inc

Atos SE

Atos SE DR

Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $0.03 by 582.76 percent. This is a 300 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $16.898 million which missed the analyst consensus estimate of $41.639 million by 59.42 percent. This is a 66.84 percent decrease over sales of $50.952 million the same period last year.

Earnings

Earnings Misses

News

Ready Capital Q2 Adj. EPS $(0.14) Misses $0.03 Estimate, Sales $16.898M Miss $41.639M Estimate

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of Mavis Tire property for $2.6 million. The property is located in a strong retail corridor in Mississippi and is corporate-operated under a under a long term, triple net lease with approximately 11 years of term remaining. The transaction was priced at a 7.0% cap rate including rent credits received at closing and exclusive of transaction costs.

FCPT

FCPT Announces Acquisition Of A Mavis Tire Property For $2.6M

Etoiles Capital Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTY#NASDAQ">EFTY</a>), a Hong Kong-headquartered financial services firm, today priced its initial public offering (the "Offering") of 1,400,000 Class A ordinary shares at $4.00 per share. The Class A ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commence trading on August 8, 2025 under the ticker symbol "EFTY."
The Company expects to receive aggregate gross proceeds of US$5.6 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 210,000 Class A ordinary shares at the public offering price, less underwriting discounts. The Offering is expected to close on or about August 11, 2025, subject to the satisfaction of customary closing conditions.
Proceeds from the Offering will be used for business expansion, technology infrastructure, strategic marketing, and general corporate purposes.

IPOs

EFTY

Etoiles Capital Group Prices $5.6M IPO Of 1.4M Shares At A Price Of $4/Share, Set To Begin Trading On August 8, 2025

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 13.71 percent. This is a 32 percent increase over losses of $(0.50) per share from the same period last year.

Earnings Beats

INMB

CORRECTION: INmune Bio Q2 Adj. EPS $(0.34) Beats $(0.39) Estimate

Guidance

PSIX

Power Solutions International Says Co Anticipates Strong Sales Growth For 2025 Compared To 2024, Driven By Expected Growth In The Power Systems End Market Including Products Supporting Data Centers, While Sales In The Industrial And Transportation End Markets Are Projected To Remain About Flat.

Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $1.30 by 16.42 percent. This is a 52.53 percent increase over earnings of $0.99 per share from the same period last year. The company reported quarterly sales of $394.163 million which beat the analyst consensus estimate of $356.587 million by 10.54 percent. This is a 24.73 percent increase over sales of $316.023 million the same period last year.

ATLC

Atlanticus Holdings Q2 EPS $1.51 Beats $1.30 Estimate, Sales $394.163M Beat $356.587M Estimate

Canaccord Genuity analyst Maria Ripps maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Hold and raises the price target from $76 to $84.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Zillow Gr, Raises Price Target to $84

Northern Dynasty Minerals Ltd. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NDM#TSX">NDM</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAK#NYSE">NAK</a>) ("Northern Dynasty" or the "Company") and its 100%-owned U.S.-based subsidiary Pebble Limited Partnership ("Pebble Partnership") provide an update on veto removal negotiations with the U.S. Government and on the recent order by Judge Gleason in the Alaska Federal District granting our motion to set a summary judgement briefing schedule for good cause shown.
&nbsp;
Judge Gleason has now set the summary briefing schedule after receiving submissions by both the plaintiffs and the defendants. Under the order, the plaintiffs (the State of Alaska, Pebble Partnership and Iliamna Natives Ltd, et al.) will file their opening briefs by October 3, 2025. The Department of Justice ("DOJ") will then file their response brief by January 2, 2026 and the plaintiffs will file their response to the DOJ's briefs by February 27, 2026. The case against the U.S. Army Corps of Engineers remains stayed.

Legal

TSX:NDM

Northern Dynasty Advances Legal Challenge To Pebble Mine Veto As Judge Sets Summary Judgment Schedule In Alaska Court

Canaccord Genuity analyst William Plovanic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Buy and lowers the price target from $59 to $24.

TNDM

Canaccord Genuity Maintains Buy on Tandem Diabetes Care, Lowers Price Target to $24

Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) reported quarterly losses of $(1.41) per share. This is a 99.45 percent increase over losses of $(256.16) per share from the same period last year.

BJDX

Bluejay Diagnostics Q2 EPS $(1.41) Up From $(256.16) YoY

CAPREIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAR#TSX">CAR</a>) reported quarterly earnings of $0.66 per share. This is a 2.64 percent increase over earnings of $0.64 per share from the same period last year. The company reported $254.434 million in sales this quarter. This is a 8.52 percent decrease over sales of $278.126 million the same period last year.

TSX:CAR

CAPREIT Q2 FFO $0.66 Up From $0.64 YoY, Sales $254.434M Down From $278.126M YoY

Canaccord Genuity analyst David Hynes maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Buy and lowers the price target from $30 to $25.

Canaccord Genuity Maintains Buy on Sprout Social, Lowers Price Target to $25

Canaccord Genuity analyst David Hynes maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Buy and raises the price target from $115 to $165.

SHOP

Canaccord Genuity Maintains Buy on Shopify, Raises Price Target to $165

Canaccord Genuity analyst Jason Tilchen maintains Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Buy and raises the price target from $15 to $17.

SGHC

Canaccord Genuity Maintains Buy on Super Group (SGHC), Raises Price Target to $17

Tucows (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCX#NASDAQ">TCX</a>) reported quarterly losses of $(1.47) per share. This is a 9.82 percent increase over losses of $(1.63) per share from the same period last year. The company reported $98.463 million in sales this quarter. This is a 10.11 percent increase over sales of $89.423 million the same period last year.

CORRECTION: Tucows Q2 Adj. EPS $(1.47) Up From $(1.63) YoY, Sales $98.463M Up From $89.423M YoY

Canaccord Genuity analyst Susan Anderson maintains Perrigo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) with a Buy and lowers the price target from $42 to $40.

PRGO

Canaccord Genuity Maintains Buy on Perrigo, Lowers Price Target to $40

Strathcona Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SCR#TSX">SCR</a>) reported quarterly earnings of $1.08 per share. This is a 1.89 percent increase over earnings of $1.06 per share from the same period last year. The company reported $1.209 billion in sales this quarter. This is a 17.87 percent decrease over sales of $1.472 billion the same period last year.

TSX:SCR

Strathcona Resources Q2 EPS $1.08 Up From $1.06 YoY, Sales $1.209B Down From $1.472B YoY

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.24 by 79.17 percent. This is a 104.76 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $386.138 million which beat the analyst consensus estimate of $376.675 million by 2.51 percent. This is a 12.06 percent decrease over sales of $439.081 million the same period last year.

CORRECTION: Nu Skin Enterprises Q2 EPS $0.43 Beats $0.24 Estimate, Sales $386.138M Beat $376.675M Estimate

Canacol Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNE#TSX">CNE</a>) reported quarterly earnings of $0.41 per share. This is a 166.13 percent increase over losses of $(0.62) per share from the same period last year. The company reported $64.809 million in sales this quarter. This is a 26.59 percent decrease over sales of $88.288 million the same period last year.

TSX:CNE

Canacol Energy Q2 EPS $0.41 Up From $(0.62) YoY, Sales $64.809M Down From $88.288M YoY

Canaccord Genuity analyst Brian McNamara maintains Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) with a Buy and lowers the price target from $186 to $162.

MIDD

Canaccord Genuity Maintains Buy on Middleby, Lowers Price Target to $162

Press Releases

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Health Care

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

Biotech

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

ATOS

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anika Therapeutics

Anixa Biosciences

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Avalo Therapeutics

Biomea Fusion

Coherus Oncology

Climb Bio

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

HilleVax

Immunic

Macrogenics

OKYO Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Quince Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Surrozen

TScan Therapeutics

Tenaya Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Zura Bio Limited - Class A Ordinary shares

Comments

Atossa Therapeutics

Atossa Therapeutics (ATOS) Opciones

Atossa Therapeutics (NASDAQ:ATOS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL